Akums Drugs Q2 Profit More Than Doubles to Rs 114.56 Cr

New Delhi: Akums Drugs and Pharmaceuticals’ consolidated net profit more than doubled to Rs 114.56 crore in the September quarter of the current fiscal, driven by continued momentum in its CDMO business, healthy demand and improved operating performance.

The company reported a 168.35 per cent increase in net profit, compared to Rs 42.69 crore in the preceding financial year, according to a regulatory filing.

Its revenue increased to Rs 1,371.29 crore for the period under review from Rs 1,049.89 crore in the year-ago period, the company said.

Total expenses rose to Rs 1,216.54 crore in Q2 FY27 from Rs 984.22 crore in the corresponding period last year.

Sanjeev Jain, Managing Director, Akums Drugs, said, “We remain committed to strengthening our position as India’s largest CDMO (contract development and manufacturing organisation) player. The demand environment continues to remain robust, reflecting the growing importance of reliable manufacturing partners. We are continuously investing in our manufacturing infrastructure and strengthening our capabilities to address the evolving requirements of our partners.”

Shares of Akums Drugs and Pharmaceuticals closed flat at Rs 731.5 apiece, down 0.05 per cent, on the BSE on Monday.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)